Keywords: gsk, faces, renewed, scrutiny, over, paxil, unsealed

GSK faces renewed scrutiny over Paxil as unsealed study claims firm "improperly" counted placebo cases

Article | 23 June 2008

Print This

GlaxoSmithKline is under renewed scrutiny over its antidepressant Paxil (paroxetine HCl), after a US study suggested that the UK drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in